Well-Positioned to Expedite the Rescheduling of Cannabinoid-Based Medicines.
MONTEREY, Calif., Dec. 19, 2025 — BRC Therapeutics (BRC), a pharmaceutical firm creating proprietary treatments for neurological and inflammatory diseases, has praised a significant executive order issued yesterday. The order would reclassify cannabis from Schedule I of the Controlled Substances Act—a category for drugs deemed to have a high potential for abuse and no accepted medical use—to the less restrictive Schedule III.
This pivotal federal policy change aligns national law with regulations already adopted by 40 states and highlights the medicinal value of cannabis-derived compounds, known as cannabinoids. The executive action is anticipated to speed up a rescheduling process begun years ago, which would significantly ease the path for developing and commercializing cannabinoid-based pharmaceuticals.
BRC already conducts its operations within a federally compliant structure under the strict supervision of the Drug Enforcement Administration (DEA), possessing all necessary DEA licenses for research and cGMP production. This landmark policy shift is expected to provide further impetus to the company’s mission of addressing significant unmet medical needs with its plant-derived cannabinoid therapeutics.
“The federal reclassification of cannabis is a defining moment for scientific research, medical practice, and the countless patients in need of new therapeutic solutions,” stated George Hodgin, CEO and Founder of BRC Therapeutics. “The Schedule I status has long been a major obstacle to research and progress. The order from yesterday signals that this substantial barrier is poised to be removed.”
BRC’s development pipeline features two investigational products undergoing clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). The regulatory change initiated by the order is expected to enable faster development and expanded manufacturing capabilities for these candidates.
“We are confident that rescheduling will stimulate more rigorous scientific investigation and pave the way for a new era of non-addictive, clinically validated treatments for pain and other conditions where cannabinoids show significant therapeutic potential,” Hodgin further commented.
About BRC Therapeutics
BRC Therapeutics (BRC) is a pharmaceutical company dedicated to creating innovative treatments that provide relief from pain and other symptoms associated with acute and chronic conditions. The company’s medicines are multimodal and incorporate cannabinoids in specific, defined ratios. BRC has established a pipeline of prescription drugs targeting neurological and inflammatory disorders. Two investigational products are currently in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). BRC is registered with the DEA and headquartered in Monterey, CA.
To learn more about BRC, visit .
Forward-Looking Statements
This press release includes forward-looking statements as defined by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties and include, but are not limited to, remarks concerning the development, application, advantages, and impacts of Biopharmaceutical Research Company’s (BRC) therapeutic product candidates and associated technology, future business and growth strategies, and anticipated clinical trial plans, including patient enrollment numbers and timelines. Forward-looking statements can often be identified by words such as “may,” “will,” “should,” “expect,” “design,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or their negatives or other comparable expressions. These statements, and others in this release that are not historical accounts, are based on management’s current expectations and assumptions and are subject to risks and uncertainties. Should these risks materialize or assumptions prove false, the company’s business, operational results, financial health, and stock price could be significantly adversely impacted. Actual outcomes and the timing of events may vary substantially from those projected in these forward-looking statements. The forward-looking statements contained in this document are made only as of its publication date, and, except as mandated by law, BTC assumes no duty to update them for subsequent events or developments.
Correction: The source company name has been updated.
SOURCE BRC Therapeutics